Last updated: December 13, 2013
Sponsor: UCB Pharma
Overall Status: Completed
Phase
3
Condition
Nasal Obstruction
Common Cold
Allergy
Treatment
N/AClinical Study ID
NCT00315523
A00415
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years
Subjects who obtain a minimum sum score, considering SAR related symptoms (meanvalue), as defined by the protocol
Exclusion
Exclusion Criteria:
Any clinically significant condition that might interfere with the treatmentevaluation, both for efficacy and safety
Have used forbidden concomitant medications as defined by the protocol
Study Design
Total Participants: 403
Study Start date:
July 01, 2006
Estimated Completion Date:
October 31, 2006
Connect with a study center
Mississauga, Ontario
CanadaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.